Just days ago, pharma major Lupin Limited made an announcement to the stock exchanges that it had received an establishment investigation report from the US Federal Drug Administration for the successful inspection of its Pithampur plant which had been subjected to an investigation in summer last year.
In the statement, Nilesh Gupta, Lupin's managing director, said, “The successful outcome of this inspection is encouraging and further validate our commitment to meeting global manufacturing standards.” Before that on April 3, the company issued another press release ...
TO READ THE FULL STORY, SUBSCRIBE NOW NOW AT JUST Rs
Key stories on business-standard.com are available to premium subscribers only.
Already a premium subscriber? LOGIN NOW
First Published: Wed, April 18 2018. 16:43 IST
